Trial Of Experimental TB Drug First In 6 Years, Revealing Poor State Of Research On Disease

Devex: New TB drug enters first trial: The good and sad news
“The maiden human trial of a potential tuberculosis drug — the first in six years — has now commenced. Known as TBA-354, the promising drug comes from a class of chemicals known to be effective against drug-sensitive and drug-resistant tuberculosis, deemed a major public health concern because it can derail progress made in TB treatment and care. … Although considered a milestone, this news also hints at the sad state of research and development for TB drugs…” (Villarino, 2/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.